AR107042A1 - Inhibidores de la tirosina quinasa de bruton y métodos de su uso - Google Patents

Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Info

Publication number
AR107042A1
AR107042A1 ARP160103789A ARP160103789A AR107042A1 AR 107042 A1 AR107042 A1 AR 107042A1 AR P160103789 A ARP160103789 A AR P160103789A AR P160103789 A ARP160103789 A AR P160103789A AR 107042 A1 AR107042 A1 AR 107042A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
haloalkyl
phenyl
optionally substituted
Prior art date
Application number
ARP160103789A
Other languages
English (en)
Spanish (es)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR107042A1 publication Critical patent/AR107042A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP160103789A 2015-12-10 2016-12-12 Inhibidores de la tirosina quinasa de bruton y métodos de su uso AR107042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
AR107042A1 true AR107042A1 (es) 2018-03-14

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103789A AR107042A1 (es) 2015-12-10 2016-12-12 Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Country Status (30)

Country Link
US (5) US10717745B2 (enExample)
EP (2) EP3386991B1 (enExample)
JP (2) JP6835846B2 (enExample)
KR (1) KR102103395B1 (enExample)
CN (2) CN108884106A (enExample)
AR (1) AR107042A1 (enExample)
AU (1) AU2016366541B2 (enExample)
BR (1) BR112018011526B1 (enExample)
CA (1) CA3007990C (enExample)
CY (1) CY1123263T1 (enExample)
DK (1) DK3386991T3 (enExample)
EA (1) EA035168B1 (enExample)
ES (1) ES2805835T3 (enExample)
HR (1) HRP20201193T1 (enExample)
HU (1) HUE049502T2 (enExample)
IL (1) IL259863B (enExample)
JO (1) JO3794B1 (enExample)
LT (1) LT3386991T (enExample)
MA (2) MA43409B1 (enExample)
MD (1) MD3386991T2 (enExample)
ME (1) ME03803B (enExample)
MX (1) MX387590B (enExample)
PL (1) PL3386991T3 (enExample)
PT (1) PT3386991T (enExample)
RS (1) RS60604B1 (enExample)
SI (1) SI3386991T1 (enExample)
SM (1) SMT202000404T1 (enExample)
TW (1) TWI729047B (enExample)
UY (1) UY37015A (enExample)
WO (1) WO2017100662A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
WO2018170220A1 (en) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
AU2019284472B2 (en) 2018-06-11 2024-05-30 Amgen Inc. KRAS G12C inhibitors for treating cancer
US12404260B2 (en) 2019-04-11 2025-09-02 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as MALT1 inhibitors
EP4089095A4 (en) * 2020-01-07 2024-03-27 Medshine Discovery Inc. DEUTERATED THIENOPYRIDINE COMPOUND
EP4301365A1 (en) * 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
MX2023014435A (es) 2021-06-04 2024-03-08 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
MX2023015147A (es) * 2021-06-30 2024-04-01 Janssen Pharmaceutica Nv Inhibidores de la tirosina quinasa de bruton y métodos de su uso.
WO2023016995A1 (en) 2021-08-09 2023-02-16 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies
MX2024010134A (es) * 2022-02-18 2024-08-27 Janssen Pharmaceutica Nv Sintesis de inhibidores de tirosina quinasa de bruton.
WO2025262118A1 (en) 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2010056875A1 (en) * 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) * 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
HRP20181109T1 (hr) * 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
SMT202000404T1 (it) 2020-09-10
BR112018011526B1 (pt) 2024-02-27
NZ742484A (en) 2021-09-24
JP6835846B2 (ja) 2021-02-24
CA3007990C (en) 2024-01-02
KR20180093974A (ko) 2018-08-22
US20190276471A1 (en) 2019-09-12
CN113121562B (zh) 2022-09-13
EP3719022B1 (en) 2026-07-08
CN108884106A (zh) 2018-11-23
IL259863A (en) 2018-07-31
US20230097422A1 (en) 2023-03-30
BR112018011526A2 (pt) 2018-11-21
EA035168B1 (ru) 2020-05-08
AU2016366541B2 (en) 2021-05-13
LT3386991T (lt) 2020-08-25
RS60604B1 (sr) 2020-08-31
PL3386991T3 (pl) 2021-03-08
SI3386991T1 (sl) 2020-08-31
TW201734021A (zh) 2017-10-01
CA3007990A1 (en) 2017-06-15
PT3386991T (pt) 2020-08-18
JO3794B1 (ar) 2021-01-31
HUE049502T2 (hu) 2020-09-28
TWI729047B (zh) 2021-06-01
EA201891378A1 (ru) 2018-12-28
JP2021073286A (ja) 2021-05-13
IL259863B (en) 2020-06-30
UY37015A (es) 2017-06-30
ME03803B (me) 2021-04-20
WO2017100662A1 (en) 2017-06-15
CN113121562A (zh) 2021-07-16
KR102103395B1 (ko) 2020-04-23
MX387590B (es) 2025-03-18
US20210101910A1 (en) 2021-04-08
EP3719022A1 (en) 2020-10-07
MA43409B1 (fr) 2020-10-28
JP7072690B2 (ja) 2022-05-20
EP3386991A1 (en) 2018-10-17
US20240383914A1 (en) 2024-11-21
US11319329B2 (en) 2022-05-03
HRP20201193T1 (hr) 2020-11-13
ES2805835T3 (es) 2021-02-15
US12065446B2 (en) 2024-08-20
US20170283430A1 (en) 2017-10-05
DK3386991T3 (da) 2020-07-13
CY1123263T1 (el) 2021-12-31
US10934310B2 (en) 2021-03-02
JP2018536686A (ja) 2018-12-13
AU2016366541A1 (en) 2018-05-31
MX2018007075A (es) 2018-11-09
EP3386991B1 (en) 2020-06-03
MD3386991T2 (ro) 2020-11-30
US10717745B2 (en) 2020-07-21
MA53110A (fr) 2021-05-12

Similar Documents

Publication Publication Date Title
AR109805A1 (es) Derivados de oxadiazol microbiocidas
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR090220A1 (es) Inhibidores de serina/treonina cinasa
AR087760A1 (es) Heterociclilaminas como inhibidores de pi3k
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR107041A1 (es) Inhibidores de la tirosina kinasa de bruton y métodos de su uso
AR101174A1 (es) Imidazopirazinas como inhibidores de lsd1
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR087328A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR092108A1 (es) Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn
AR106099A1 (es) Compuestos bicíclicos como inhibidores duales de atx / ca
ES2620668T3 (es) Derivados de amidas y sulfonamidas amido espirocíclicas
AR106100A1 (es) Compuestos bicíclicos como inhibidores duales atx / ca
AR090005A1 (es) Imidazo[1,2-a]pirimidinas y piridinas sustituidas
AR087870A1 (es) Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
AR093504A1 (es) 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR090572A1 (es) Derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR097756A1 (es) Derivados de fenilalanina sustituidos
AR103582A1 (es) Ciclopropabenzofuranil-piridopirazindionas
AR111252A1 (es) Compuestos de isoxazol carboxamida y usos de los mismos

Legal Events

Date Code Title Description
FG Grant, registration